Last update: March 29, 2016
Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.
Selective estrogen receptor modulator. Estrogen agonist in bone and estrogen receptor antagonist in breast and uterine tissue.
Indicated in treating osteoporosis and preventing breast cancer.
Raloxifene does not alter prolactin secretion in premenopausal women but increases levels of estradiol and sex-hormone binding globulin (BGSH).
At last update no published data on excretion in breast milk were found.
Pharmacokinetic data (large volume of distribution, moderately high molecular weight and high percentage of protein binding) make it unlikely milk passage of significant amounts.
Low oral bioavailability hinders the passage into infant plasma from ingested milk except in preterm neonates and immediate neonatal period, because an increased intestinal permeability can appear.
Although short-term treatments may be of low risk during breastfeeding, the anti-estrogenic effect on breast tissue, a prolonged use is not recommended.
We do not have alternatives for ραλοξιφαίνη υδροχλωρική.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM